Kura Oncology, Inc. to Post FY2022 Earnings of $2.71 Per Share, Wedbush Forecasts (KURA)

Kura Oncology, Inc. (NASDAQ:KURA) – Wedbush issued their FY2022 earnings per share (EPS) estimates for shares of Kura Oncology in a report issued on Thursday. Wedbush analyst R. Driscoll expects that the company will post earnings per share of $2.71 for the year. Wedbush has a “Buy” rating and a $19.00 price objective on the stock.

Several other equities analysts have also issued reports on the stock. Cann reaffirmed a “buy” rating and issued a $30.00 price target on shares of Kura Oncology in a report on Friday, February 16th. Citigroup set a $28.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a report on Friday, February 16th. Zacks Investment Research raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Thursday, February 8th. BidaskClub raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, January 24th. Finally, Oppenheimer set a $18.00 price objective on shares of Kura Oncology and gave the company a “buy” rating in a report on Monday, December 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $21.67.

Kura Oncology (NASDAQ:KURA) traded down $0.55 during midday trading on Monday, reaching $22.20. 769,300 shares of the company’s stock traded hands, compared to its average volume of 388,309. The company has a quick ratio of 13.48, a current ratio of 13.48 and a debt-to-equity ratio of 0.07. Kura Oncology has a fifty-two week low of $5.90 and a fifty-two week high of $24.02. The stock has a market capitalization of $687.40, a price-to-earnings ratio of -14.32 and a beta of 4.94.

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in Kura Oncology by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 166,914 shares of the company’s stock valued at $2,553,000 after purchasing an additional 3,255 shares during the last quarter. American International Group Inc. boosted its holdings in Kura Oncology by 42.0% in the fourth quarter. American International Group Inc. now owns 13,574 shares of the company’s stock valued at $208,000 after purchasing an additional 4,012 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Kura Oncology by 24.5% in the third quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock valued at $471,000 after purchasing an additional 6,200 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Kura Oncology by 12.9% in the fourth quarter. Bank of New York Mellon Corp now owns 66,936 shares of the company’s stock worth $1,024,000 after acquiring an additional 7,655 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of Kura Oncology by 48.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 29,222 shares of the company’s stock worth $447,000 after acquiring an additional 9,590 shares during the period. 62.83% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/21/kura-oncology-inc-to-post-fy2022-earnings-of-2-71-per-share-wedbush-forecasts-kura.html.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply